11don MSNOpinion
Why you should be pleased we run trials on nudges, even if you don't like nudges (or trials)
Last year, we ran a randomized controlled trial working with frontline workers in the homelessness sector, which aimed to ...
Atossa Therapeutics (ATOS) announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer ...
ALS medication AMX0114 has been well tolerated in early clinical testing, and is now moving to a second, higher-dose trial group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback